STOCK MARKET BSE NSE

Hetero's Tocilizumab biosimilar gets emergency use authorisation from DCGI for COVID treatment

Hetero's biologics arm, Hetero Biopharma will manufacture the drug at its dedicated biologics facility, based at Jadcherla in Hyderabad.

Published: 06th September 2021 02:20 PM  |   Last Updated: 06th September 2021 02:20 PM   |  A+A-

Covid Vaccine, Coronavirus

Representational Image (File Photo | AFP)

By PTI

NEW DELHI: Drug firm Hetero on Monday said it has received emergency use authorisation from Drug Controller General of India (DCGI) for its biosimilar version of Tocilizumab for treatment of COVID-19 in hospitalised adults.

The company will market the drug under the brand name 'Tocira', Hetero said in a statement.

This authorisation will enable medical practitioners to use the drug for the treatment of COVID-19 in hospitalised adults who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation, it added.

"This approval is extremely crucial for supply security in India considering a global shortage of Tocilizumab. We will be working closely with the government to ensure equitable distribution," Hetero Group Chairman, B Partha Saradhi Reddy said.

Tocira will be marketed by Hetero's associate company Hetero Healthcare in India.

Hetero's biologics arm, Hetero Biopharma will manufacture the drug at its dedicated biologics facility, based at Jadcherla in Hyderabad, the statement said.

The company's Tocilizumab 400mg/20ml is the biosimilar version of Roche's Actemra/RoActemra, and will be available from September-end, it added.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp